MRVI MARAVAI LIFESCIENCES HLDGS I revenue, earnings and financials

For the quarter ended June 30, 2026, MARAVAI LIFESCIENCES HLDGS I reported revenue of $51.4M (up 8.5% from a year earlier), net income of −$12.4M and diluted EPS of −$0.08; over the last four quarters revenue was $209M and net income −$77.4M; for the fiscal year ended December 2025 revenue was $186M, down 28.3% on the year before.

MRVI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $186M, gross profit $34.0M, operating income −$215M, net income −$131M (margin -70.4%), EPS −$0.90
• Fiscal year ended Dec 2024: revenue $259M, gross profit $108M, operating income −$236M, net income −$145M (margin -55.9%), EPS −$1.05
• Fiscal year ended Dec 2023: revenue $289M, gross profit $140M, operating income −$31.6M, net income −$138M (margin -47.9%), EPS −$0.90
• Fiscal year ended Dec 2022: revenue $883M, gross profit n/a, operating income $574M, net income $491M (margin 55.6%), EPS $1.67
• Fiscal year ended Dec 2021: revenue $799M, gross profit n/a, operating income $555M, net income $469M (margin 58.7%), EPS $1.56

MRVI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $51.4M (up 8.5% year over year), net income −$12.4M, EPS −$0.08
• Quarter ended Mar 31, 2026: revenue $65.8M (up 40.5% year over year), net income −$3.73M, EPS −$0.02
• Quarter ended Dec 31, 2025 (from the annual report): revenue $49.9M (down 11.8% year over year), net income −$35.7M, EPS −$0.24
• Quarter ended Sep 30, 2025: revenue $41.6M (down 39.7% year over year), net income −$25.6M, EPS −$0.18
• Quarter ended Jun 30, 2025: revenue $47.4M (down 31.7% year over year), net income −$39.6M, EPS −$0.27
• Quarter ended Mar 31, 2025: revenue $46.9M (down 27.0% year over year), net income −$29.9M, EPS −$0.21
• Quarter ended Dec 31, 2024 (from the annual report): revenue $56.6M (down 23.7% year over year), net income −$25.9M, EPS −$0.21
• Quarter ended Sep 30, 2024: revenue $69.0M (up 3.2% year over year), net income −$97.1M, EPS −$0.68
• Quarter ended Jun 30, 2024: revenue $69.4M (up 0.7% year over year), net income −$9.79M, EPS −$0.07
• Quarter ended Mar 31, 2024: revenue $64.2M (down 18.8% year over year), net income −$12.1M, EPS −$0.09
• Quarter ended Dec 31, 2023 (from the annual report): revenue $74.1M (down 63.8% year over year), net income −$125M, EPS −$0.80
• Quarter ended Sep 30, 2023: revenue $66.9M (down 65.0% year over year), net income −$6.46M, EPS −$0.05
• Quarter ended Jun 30, 2023: revenue $68.9M (down 71.6% year over year), net income −$6.54M, EPS −$0.05
• Quarter ended Mar 31, 2023: revenue $79.0M (down 67.7% year over year), net income −$67.0K, EPS $0.00
• Quarter ended Dec 31, 2022 (from the annual report): revenue $205M (down 10.4% year over year), net income $308M, EPS $0.30
• Quarter ended Sep 30, 2022: revenue $191M (down 6.6% year over year), net income $44.5M, EPS $0.34
• Quarter ended Jun 30, 2022: revenue $243M (up 11.5% year over year), net income $71.2M, EPS $0.53
• Quarter ended Mar 31, 2022: revenue $244M (up 64.8% year over year), net income $66.9M, EPS $0.50
• Quarter ended Dec 31, 2021 (from the annual report): revenue $228M, net income $343M, EPS $0.44
• Quarter ended Sep 30, 2021: revenue $205M, net income $54.0M, EPS $0.44

MRVI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$57.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $7.47M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $126M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $536M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $369M, share buybacks $0

MRVI balance sheet

• Jun 30, 2026: cash $70.1M, total assets $604M, total liabilities $248M, shareholders' equity $205M, long-term debt $146M
• Mar 31, 2026: cash $166M, total assets $713M, total liabilities $344M, shareholders' equity $212M, long-term debt $236M
• Dec 31, 2025: cash $217M, total assets $771M, total liabilities $398M, shareholders' equity $212M, long-term debt $286M
• Sep 30, 2025: cash $244M, total assets $849M, total liabilities $417M, shareholders' equity $245M, long-term debt $287M
• Jun 30, 2025: cash $270M, total assets $897M, total liabilities $429M, shareholders' equity $266M, long-term debt $288M
• Mar 31, 2025: cash $285M, total assets $960M, total liabilities $429M, shareholders' equity $301M, long-term debt $289M
• Dec 31, 2024: cash $322M, total assets $1.01B, total liabilities $431M, shareholders' equity $325M, long-term debt $290M
• Sep 30, 2024: cash $578M, total assets $1.28B, total liabilities $666M, shareholders' equity $345M, long-term debt $516M

What is MRVI's revenue?

MARAVAI LIFESCIENCES HLDGS I reported $209M of revenue over its last four quarters, through June 30, 2026.

Is MRVI profitable?

No. MARAVAI LIFESCIENCES HLDGS I lost $77.4M over the last four quarters.

What is MRVI's EPS?

Diluted earnings per share over the last four quarters were −$0.52; −$0.08 in the latest quarter.

MRVI ownership and insider trades · All stocks